Monotherapy trial design: Conversion versus de novo

Epilepsy Research

Volumn 45, Issue 1-3, 2001, Pages 75-78

  Kälviäinen, Reetta ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antiepileptic drugs; Comparative trials; Monotherapy trials

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; TIAGABINE; VALPROIC ACID;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EPILEPSY; EPILEPTOGENESIS; FOLLOW UP; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEIZURE; TREATMENT OUTCOME;

ANTICONVULSANTS; CLINICAL TRIALS; EPILEPSY; HUMANS; RESEARCH DESIGN;

EID: 0034927888     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(01)00222-4     Document Type: Conference Paper

References (6)

1. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy
2. Monotherapy clinical trials of new antiepileptic drugs: Design, indications, and controversies
3. Slow versus fast drug switch from established AED to tiagabine
4. Innovative monotherapy trial design for the assessment of antiepileptic drugs: A critical appraisal
5. Monotherapy trial with the new antiepileptic drugs: Study designs, practical relevance and ethical implications